Pfizer Jumps Over 7% On AstraZeneca Deal
Pfizer entered into a pact with AstraZeneca AB to acquire the 'Neksium' brand in India for Rs 75 crore.01-06-2017
01-06-2017
Updates
This is to inform you that the Company has entered into an Acquisition Agreement with AstraZeneca AB, Sweden ('AstraZeneca'), pursuant to which the brand 'Neksium' is being acquired by the Company in India for a consideration of Rs. 75 Crores, subject to completion of necessary conditions precedent. Neksium (esomeprazole) complements the Company's existing product portfolio in the gastrointestinal (GI) therapeutic area. We request you to kindly take the above on record.31-05-2017
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations')
Pursuant to Regulation 30 of the Listing Regulations, please find attached details of the meeting scheduled with an Analyst/Institutional Investor. Please note that the above schedule is subject to change on account of exigencies on the part of the Analyst/Institutional Investor or the Company. This schedule shall also be displayed on the website of the Company - www.pfizerindia.com in compliance with the Regulation 46 of the Listing Regulations.29-05-2017
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations')
Pursuant to the Regulation 30 of the Listing Regulations, we enclose herewith the transcript of the tele conference call with the analysts held on May 18, 2017, to discuss the Company's financial performance for the quarter and the financial year ended March 31, 2017. The aforesaid information will be displayed on the website of the Company in compliance with Regulation 46 of the Listing Regulations.19-05-2017
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations') - Analyst Teleconference
Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform you that a teleconference has been scheduled with the Analysts on Thursday, May 18, 2017, at 4.00 p.m. to discuss the Company's financial performance for the quarter and the financial year ended March 31, 2017. The details of the teleconference are uploaded on the website: www.pfizerindia.com.17-05-2017
Q4 result update: Pfizer's net profit falls sharply in fourth quarter
Pharma firm Pfizer Ltd has reported a steep 21.98% dip in standalone net profits, a decline to Rs 68.04 crores for its Q4 this financial year. The total income for the quarter came in at Rs. 481.9 crore, 14.7% down compared to the same quarter last year. The company's EBITDA margin in Q4 fell by 243 bps. The company however recorded net profit growth for the entire year, up 10.4% in FY17 compared to FY16. The board of directors of the company has recommended a normal dividend of Rs 15 per equity share of Rs 10 each and a special dividend of Rs 5 per share due to exceptional income.07-05-2017
Pfizer Q4 net profit falls 22% to Rs68 crore
Pfizer Q4 total income stood at Rs481.97 crore as against Rs563.57 crore in the year-ago period06-05-2017
Press Release
Please find enclosed press release for the financial results for the quarter and financial year ended March 31, 2017.06-05-2017
Updates
Pursuant to regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their Meeting held today have re-appointed Mr. Vivek Dhariwal (DIN: 02826679) as an Whole-time Director designated as Executive Director, Technical Operations with effect from May 21, 2017 for a term of 5 years. The re-appointment of Mr. Vivek Dhariwal will be subject to the...06-05-2017